CanSinoBIO signs LOI with Pakistan’s AGP to explore PCV13i vaccine opportunitiesPUBT·Jul 21 at 12:26 AM688185+1.43%06185+0.43%
CanSino says China regulator accepts Menhycia label expansion filing to age 17PUBT·Jul 19 at 05:08 AM06185+0.43%688185+1.43%
CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South AmericaAsian Corporate Newswire·Jun 29 at 04:21 AM06185+0.43%688185+1.43%
CanSino Biologics, Inc. Class H (6185) Receives a Buy from UBSTip Ranks·Jun 26 at 07:26 PM06185+0.43%
CanSino Wins Argentine Approval for Menhycia Vaccine as Global Push AcceleratesTip Ranks·Jun 25 at 04:40 AM688185+1.43%06185+0.43%
CanSino Launches First-in-Class 24-Valent Pneumococcal Vaccine TrialTip Ranks·May 25 at 07:15 PM688185+1.43%588130+0.82%
UBS Cuts CANSINOBIO TP to HKD52.4; 1Q26 Results In LineAASTOCKS News·Apr 29 at 10:53 PM06185+0.43%688185+1.43%
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International ExpansionAsian Corporate Newswire·Apr 28 at 06:20 AM06185+0.43%688185+1.43%
Star product market expansion drives CanSinoBIO to turn a profitBambooWorks·Mar 7 at 08:01 AM516930+1.04%588130+0.82%
Meningitis Shot Delivers Dose Of Good Cheer For CanSinobenzinga_article·Mar 5 at 07:03 AM159316-0.18%159615+0.59%
